News
Explore the latest stories and publications from NCATS and our partners, see upcoming events, or explore the variety of resources we provide to better understand translational science and our work.
News
Read the latest news from NCATS and its collaborators whose research is supported through the Center’s programs, or follow coverage of NCATS' translational research activities through national and local media.
NIH Partnership Establishes New Gene Therapy Immunology and Standards Laboratory
April 23, 2026 - Grantee/Partner News
- Platform Vector Gene Therapy (PaVe-GT)
Transparency and Early Planning Are Key in Increasing Efficiency of Gene Therapy Development for Rare Diseases
February 26, 2026 - NCATS News
- Platform Vector Gene Therapy (PaVe-GT)
PaVe-GT scientists underscore strategy, framework and early interaction with the FDA to align preclinical and clinical efforts in AAV gene therapy translation.
Read ArticleNIH Strategizes to Streamline Gene Therapy Development
May 2, 2024 - Media Coverage
- Bespoke Gene Therapy Consortium (BGTC)
- Platform Vector Gene Therapy (PaVe-GT)
- Somatic Cell Genome Editing (SCGE)
P.J. Brooks, Ph.D., on Working to Bring Gene Therapy Development to More Neuromuscular Disorders
March 5, 2024 - Media Coverage
- Bespoke Gene Therapy Consortium (BGTC)
- Platform Vector Gene Therapy (PaVe-GT)
Propelling Cures With Genetics Research: Interview With Joni L. Rutter, PhD, Director of the National Center for Advancing Translational Sciences at NIH
December 14, 2023 - Grantee/Partner News
- 3-D Tissue Bioprinting
- Bespoke Gene Therapy Consortium (BGTC)
- Clinical and Translational Science Awards (CTSA) Program
- New Therapeutic Uses (NTU)
- Platform Vector Gene Therapy (PaVe-GT)
- Rare Diseases Clinical Research Network (RDCRN)
- Somatic Cell Genome Editing (SCGE)
- Therapeutics for Rare and Neglected Diseases (TRND)
- Tissue Chip for Drug Screening
NIH Gene Therapy Team Reveals Its Path to FDA Orphan Drug and Rare Pediatric Disease Designations
March 29, 2023 - NCATS News
- Our Impact on Rare Diseases
- Our Impact on Research Operations
- Platform Vector Gene Therapy (PaVe-GT)
When NCATS received an Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA), it marked a key accomplishment for researchers in the NIH's Platform Vector Gene Therapy (PaVe-GT) project.
NIH, FDA and 15 Private Organizations Join Forces to Increase Effective Gene Therapies for Rare Diseases
October 27, 2021 - NCATS News
- Bespoke Gene Therapy Consortium (BGTC)
- Platform Vector Gene Therapy (PaVe-GT)
NIH, FDA and 15 private organizations partnered to create the Bespoke Gene Therapy Consortium to speed development of FDA-approved gene therapies for rare diseases. The effort is co-led by NCATS and managed by FNIH.
PaVe-GT: Collaborative NIH Effort Aimed at Creating a Gene Therapy Playbook, Making Rare Disease Treatments More Accessible
November 30, 2020 - NCATS News
- Our Impact on Rare Diseases
- Platform Vector Gene Therapy (PaVe-GT)
The Platform Vector Gene Therapy (PaVe-GT) initiative aims to make gene therapy development and clinical testing more streamlined and less expensive — and potentially more accessible to millions of people with rare diseases.